Donor immune cells take on stubborn leukemia in new trial
NCT ID NCT07026942
First seen Nov 12, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study tests a treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially engineered immune cells (CD33 CAR-NK cells) from a healthy donor to target and kill cancer cells. The trial has two phases: first to find the safest dose, then to see how well it works. Participants receive chemotherapy followed by one or two infusions of these cells and are monitored closely for side effects and remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED / REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.